<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31866">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012218</url>
  </required_header>
  <id_info>
    <org_study_id>331-13-001</org_study_id>
    <nct_id>NCT02012218</nct_id>
  </id_info>
  <brief_title>Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy</brief_title>
  <official_title>A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects'
      subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who
      have responded inadequately to preceding adjunctive drug therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change from Baseline to Week 6 in the MADRS total score.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Major Depressive Disorder (MDD)</condition>
  <arm_group>
    <arm_group_label>ADT+Brex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADT+Brex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT+Brex</intervention_name>
    <arm_group_label>ADT+Brex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of MDD

          -  In current major depressive episode of ≥ 8 weeks in duration and includes an
             inadequate response to at least 1 adjunctive treatment.

          -  Positive history of at least 1 additional failure to an adequate monotherapy
             antidepressant treatment.

          -  HAM-D17 total score≥ 18

          -  Currently receiving SSRI of SNRI with adjunctive treatment for at least 6 weeks
             before screening.

          -  Willing to discontinue use of all prohibited psychotropic medications

          -  Historical positive serological results for HIV, hepatitis B/C

          -  Able to provide written informed consent prior to the initiation of any
             protocol-required procedures

          -  Subjects who could potentially benefit from adjunctive treatment with Brexpiprazole

        Exclusion Criteria:

          -  Sexually active women of childbearing potential

          -  Male subjects not practicing 2 different methods of birth control

          -  Females who are breastfeeding and/or who have a positive pregnancy test result

          -  Subjects who have received ECT for the current major depressive episode.

          -  Subjects who have had an inadequate response to ECT

          -  Current need for involuntary commitment or who have been hospitalized within 4 weeks
             of screening

          -  Current Axis I (DSM-IV-TR)

          -  Current Axis II (DSM-IV-TR)

          -  Subjects experiencing hallucinations, delusions, or any psychotic symptomatology in
             the current major depressive episode.

          -  Subjects receiving new onset psychotherapy.

          -  Subjects who answer &quot;Yes&quot; on the C-SSRS Suicidal Ideation Item 4, Item 5, or on any
             of the 5 C-SSRS Suicidal Behavior Items

          -  Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the
             past 180 days

          -  Hypothyroidism or hyperthyroidism

          -  Clinically significant neurological, hepatic, renal, metabolic, haematological,
             immunological, cardiovascular, pulmonary, or gastrointestinal disorders

          -  Currently treated with insulin for diabetes

          -  Uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension

          -  Known ischemic heart disease or history of myocardial infarction, congestive heart
             failure, angioplasty, stenting, or coronary artery bypass surgery

          -  Epilepsy or history of seizures

          -  Positive drug screen

          -  The following laboratory test and ECG results are exclusionary:

               1. Platelets ≤ 75,000/mm3

               2. Hemoglobin ≤ 9 g/dL

               3. Neutrophils, absolute ≤ 1000/mm3

               4. AST &gt; 2 × ULN

               5. ALT &gt; 2 × ULN

               6. CPK &gt; 3 × ULN, unless discussed with and approved by the medical monitor

               7. Creatinine ≥ 2 mg/dL

               8. HbA1c ≥ 7.0%

               9. Abnormal free T4 (Note: Free T4 is measured only if result for TSH is abnormal.)

              10. QTcF ≥ 470 msec for females and ≥ 450 msec for males

          -  Treatment with an MAOI or EMSAM within 14 days of the Baseline visit.

          -  Use of benzodiazepines and/or hypnotics within 7 days prior to the first dose of IMP

          -  Use of oral neuroleptics within 7 days prior or long-acting approved atypical
             antipsychotics ≤ 1 full cycle plus ½ cycle prior to the first dose of IMP

          -  Subjects who would be likely to require prohibited concomitant therapy during the
             trial.

          -  Subjects who previously participated in any prior brexpiprazole trial

          -  History of neuroleptic malignant syndrome or serotonin syndrome

          -  History of true allergic response to more than one class of medications

          -  Prisoners or subjects who are compulsorily detained for treatment of either a
             psychiatric or physical illness.

          -  Subjects who participated in a clinical trial within the last 180 days or who
             participated in more than 2 clinical trials within the past year.

          -  Any subject who, in the opinion of the investigator or medical monitor, should not
             participate.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network, Inc.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Walling, MD</last_name>
      <phone>714-799-7799</phone>
      <email>davidwalling@cnstrial.com</email>
    </contact>
    <investigator>
      <last_name>David Walling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Viking Clinical Research, Ltd.</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>92591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sana Johnson-Quijada, MD</last_name>
      <phone>951-695-6238</phone>
      <email>sana@vikingcr.com</email>
    </contact>
    <investigator>
      <last_name>Sana Johnson-Quijada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Pharmacology</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Harper, MD</last_name>
      <phone>407-425-5100</phone>
      <email>lharper@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Linda Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carman Research</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Carman, MD</last_name>
      <phone>770-333-0093</phone>
      <email>jsc@carmanresearch.com</email>
    </contact>
    <investigator>
      <last_name>John Carman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goldpoint Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Saini, MD</last_name>
      <phone>317-229-6202</phone>
      <email>rsaini@goldpointcr.com</email>
    </contact>
    <investigator>
      <last_name>Richard Saini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Clinic</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizar El-Khalili, MD</last_name>
      <phone>765-446-9394</phone>
      <email>elkhalilmd@aol.com</email>
    </contact>
    <investigator>
      <last_name>Nizar El-Khalili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Jonas, MD</last_name>
      <phone>410-602-1440</phone>
      <email>ajonas@pharmasiteresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alan Jonas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Mezhebovsky, MD</last_name>
      <phone>617-477-4868</phone>
      <email>bct@bostontrials.com</email>
    </contact>
    <investigator>
      <last_name>Irina Mezhebovsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates, Inc.</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Gruber, MD</last_name>
      <phone>781-849-7766</phone>
      <email>dralangruber@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alan Gruber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rochester Center for Behavioral Medicine</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Young, MD</last_name>
      <phone>248-608-8800</phone>
      <email>jyoung@rcbm.net</email>
    </contact>
    <investigator>
      <last_name>Joel Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Clinical Trials</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Mofsen, MD</last_name>
      <phone>314-771-6387</phone>
      <email>rmofsen@slct.co</email>
    </contact>
    <investigator>
      <last_name>Rick Mofsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leon Rosenberg, MD</last_name>
      <phone>856-857-9500</phone>
      <email>lrosenberg@cfef.com</email>
    </contact>
    <investigator>
      <last_name>Leon Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Behavioral Medical Research of Staten Island</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Breving, MD</last_name>
      <phone>718-351-3319</phone>
      <email>j.breving@bmrsi.com</email>
    </contact>
    <investigator>
      <last_name>Joel Breving, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richard H. Weisler, MD, PA</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Weisler, MD</last_name>
      <phone>919-872-5900</phone>
      <email>rweisler@weislermd.com</email>
    </contact>
    <investigator>
      <last_name>Richard Weisler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center MCRC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417-3445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Dueno, MD</last_name>
      <phone>937-424-1050</phone>
      <email>ODueno@midwestclinical.com</email>
    </contact>
    <investigator>
      <last_name>Otto Dueno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willis Holloway, MD</last_name>
      <phone>405-603-8068</phone>
      <email>wholloway@cuttingedgeresearch.org</email>
    </contact>
    <investigator>
      <last_name>Willis Holloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beal Essink, MD</last_name>
      <phone>503-276-6224</phone>
      <email>beal.essink@occi.org</email>
    </contact>
    <investigator>
      <last_name>Beal Essink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigations, Inc.</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Horwitz, MD</last_name>
      <phone>503-540-0100</phone>
      <email>salem@occi.org</email>
    </contact>
    <investigator>
      <last_name>Alexander Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Center for Clinical Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Gross, MD</last_name>
      <phone>610-820-0342</phone>
      <email>pgross@lehighcenter.com</email>
    </contact>
    <investigator>
      <last_name>Paul Gross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lincoln Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Whalen, MD</last_name>
      <phone>401-333-3435</phone>
      <email>jw@lincolnresearch.org</email>
    </contact>
    <investigator>
      <last_name>James Whalen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Strategies of Memphis, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul King, MD</last_name>
      <phone>901-685-8890</phone>
      <email>kingmd@researchmemphis.com</email>
    </contact>
    <investigator>
      <last_name>Paul King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Future Search Trials of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Downing, MD</last_name>
      <phone>214-369-2600</phone>
      <email>michaeld@fstrials.com</email>
    </contact>
    <investigator>
      <last_name>Michael Downing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NeuropsychiatricAssociates</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Groft, MD</last_name>
      <phone>802-457-4904</phone>
      <phone_ext>102</phone_ext>
      <email>agroft@npavt.org</email>
    </contact>
    <investigator>
      <last_name>Alicia Groft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frontier Institute</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Tran, MD</last_name>
      <phone>509-458-2405</phone>
      <email>jtranfi@smhca.org</email>
    </contact>
    <investigator>
      <last_name>John Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>December 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder, Depression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
